$CNXU News
Last published 1d ago
- 1d agoCNXUConexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue RestorationGlobeNewswireCXU™ formula already evaluated with human collagen in the 12-month P.R.O.O.F.™ preclinical study; first pilot batch of Conexeu’s own human collagen met predefined Company specifications
- 3w agoCNXUConexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and DirectorsGlobeNewswireRENO, Nev., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an
- 1mo agoCNXUSOLVVCELAXGN+1Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.GlobeNewswireRENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a
- 2mo agoCNXUESTAEOLSINMD+1A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to CapturePR NewswireEquity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare....
- 2mo agoCNXUConexeu Sciences Sets September and October 2026 Conference ScheduleGlobeNewswireRENO, Nev., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a preclinical-stage biotechnology company advancing an investigational
- 2mo agoCNXULLYNVOABBV+1A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.GlobeNewswireIssued on behalf of Conexeu Sciences Inc. NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - For as long as aesthetic medicine has existed, its central promise has been to replace what time
- 2mo agoCNXUNVDAAMDTSLA+1The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too.GlobeNewswireNEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - The most valuable companies of the past two decades share a trait that is easy to miss: they didn’t win by competing inside an existing
- 2mo agoCNXUConexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to RegenerationGlobeNewswirePeer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu’s CXU™ Platform Highlights
- 3mo agoCNXUESTALLYABBV+1The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built ForGlobeNewswireRENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - The weight-loss drug boom has been one of the defining healthcare stories of the decade, and its success has created a second-order
- 3mo agoCNXUVCELAXGNKRYS+1Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill ItGlobeNewswireRENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy
- 3mo agoCNXUConexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue RegenerationGlobeNewswireRENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a preclinical-stage biotechnology company advancing an investigational tissue-restoration
- 3mo agoABBVJNJINMDANIK+1Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next OneGlobeNewswireNEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator
- 3mo agoCNXUVLOTALOPBF+1The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.PR NewswireEquity Insider News Commentary — Every so often, a wave of demand in one corner of medicine spills over and creates an entirely new market next door. ...
- 3mo agoCNXUFAANABCVE+1A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes NextGlobeNewswireIssued on behalf of Conexeu Sciences Inc. As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (NASDAQ:CNXU)
- 4mo agoCNXUThe GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for ItGlobeNewswireHighlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed. History demonstrates the value of
- 4mo agoCNXUABBVNVOEOLS+2One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical AestheticsPR NewswireIn regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one...
- 4mo agoCNXUABBVLLYNVOA $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill ItPR NewswireEquity Insider News Commentary, The weight-loss drug boom is one of the defining medical stories of the decade, and its second-order effects are only ...
- 4mo agoCNXUA $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to FillGlobeNewswireStudy Highlights P.R.O.O.F study complete, marking an important catalyst. Conexeu has completed its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program, which provides the
- 4mo agoCNXUGALDYINMDESTA+1The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for ItGlobeNewswireIssued on behalf of Conexeu Sciences Inc. With Galderma now presenting clinical data on treating medication-driven facial volume loss, the GLP-1 aesthetics category has gone mainstream — and Conexeu Sciences Inc.
- 4mo agoCNXUConexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue PlatformGlobeNewswireRENO, Nev., June 25, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, announced the opening of its new
- 4mo agoCNXUIARTMDXGORGO+1Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild ItselfGlobeNewswireIssued on behalf of Conexeu Sciences Inc. A sector analysis of regenerative medicine — the science of restoring tissue rather than merely replacing it — and where a new generation of platform companies is trying to fit
- 4mo agoCNXUIARTMDXGORGO+1The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding ItGlobeNewswireIssued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow
- 4mo agoCNXUSNNABBVESTA+1Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma FirepowerPR NewswireAmerican News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then ...
- 4mo agoCNXUConexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq ListingGlobeNewswireRENO, Nev., June 15, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, today announced additions to its leadership team,
- 5mo agoCNXUConexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care ProgramGlobeNewswireRENO, Nev., June 08, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company") today announced progress in manufacturing scale up and standardized formulation methods with its contract
- 5mo agoCNXUConexeu Sciences to Ring Nasdaq Bell on June 10, 2026GlobeNewswireRENO, Nev., June 03, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, will ring the Nasdaq Closing Bell
- 5mo agoCNXUIARTBVSORGO+1The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement PartsPR NewswireFor more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't...
- 5mo agoCNXUUPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative MedicineGlobeNewswireRENO, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, today announced the launch of a
- 5mo agoCNXUESTAINMDPCRX+1After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast InsteadGlobeNewswireConexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue
- 5mo agoAXGNCNXUDDDESTA+1The Newest Name on Nasdaq Wants to Help the Body Rebuild ItselfGlobeNewswireIssued on behalf of Conexeu Sciences Inc.A biotech debut out of Reno is betting that the next wave of medicine won't replace tissue — it'll grow it back.NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News
- 5mo agoCNXUIARTEOLSBVS+1Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItPR NewswireUSA News Group News Commentary — Wall Street's regenerative medicine bench just got one name deeper. On May 21, 2026, Conexeu Sciences Inc. (Nasdaq:...
- 5mo agoCNXUELUTPCRXSNN+1A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth WatchingGlobeNewswireFive companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary —